SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 96,000 shares, a decline of 63.1% from the November 15th total of 260,200 shares. Based on an average daily trading volume, of 985,100 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.9% of the shares of the stock are short sold.

SciSparc Trading Up 5.9 %

SPRC stock traded up $0.02 on Friday, reaching $0.27. 575,590 shares of the company’s stock were exchanged, compared to its average volume of 1,515,238. SciSparc has a twelve month low of $0.21 and a twelve month high of $6.78. The stock has a fifty day moving average of $0.23 and a 200-day moving average of $0.44.

Hedge Funds Weigh In On SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC acquired a new position in shares of SciSparc Ltd. (NASDAQ:SPRC) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc at the end of the most recent quarter. 25.06% of the stock is currently owned by institutional investors.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.